Please login to the form below
clinical benefit
This page shows the latest clinical benefit news and features for those working in and with pharma, biotech and healthcare.
FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
In the post, they explained that although evidence from the Aduhelm programme was suggestive of clinical benefit, they came to the conclusion – alongside the FDA’s Peripheral and Central Nervous System ... Advisory Committee – that the trial data
Latest news
-
FDA narrows label for Biogen’s Aduhelm to only include mild forms of Alzheimer’s disease
dementia. The FDA initially approved Aduhelm (aducanumab) for the treatment of all patients with Alzheimer’s disease, despite clinical trials only evaluating the anti-amyloid antibody in patients with milder forms ... The FDA approved Aduhelm via its
-
Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease
Clinical benefit correlated with increase in target biomarker SIGMAR1. Anavex Life Sciences’ investigational drug candidate ANAVEX2-73 led to improvements in clinical efficacy endpoints, including cognitive and non-cognitive measures, in
-
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
FDA is requiring Biogen to conduct a new randomised, controlled clinical trial to verify the drug’s clinical benefit for Alzheimer’s patients. ... If Aduhelm fails to prove its clinical benefit for patients, the FDA can choose to withdraw the
-
Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO
Clinical Oncology (ASCO) annual meeting. ... By providing a treatment which significantly reduces the risk of breast cancer returning in these high-risk patients, we hope Lynparza will set a new benchmark demonstrating sustained clinical benefit.
-
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
clinical benefit rate of 60%.
FDA narrows label for Biogen’s Aduhelm to only include mild forms of Alzheimer’s disease
Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO
More from news
Approximately 1 fully matching, plus 179 partially matching documents found.
Latest Intelligence
-
Alzheimer’s disease: the search for a cure
Not all of the drugs entering clinical trials will go on to benefit patients, so we are increasing the probability of successfully delivering a disease- modifying treatment by targeting disease processes ... We now know that the diseases that cause
-
The search for effective drug treatments for COVID-19
In response to the WHO study, a Gilead spokesperson said that there was “more robust evidence from multiple randomised, controlled studies published in peer-reviewed journals validating the clinical benefit of ... Lastly, the two randomised,
-
Addressing the payer-regulator evidence gap in early-stage cancer
Baseline survival times are longer in early-stage disease, and other measures of clinical benefit become relevant such as avoidance of recurrence and quality of life. ... Which alternative endpoints can assess clinical benefit in early-stage disease?
-
Alzheimer’s: the search for a cure
The analysis of the expanded data set for one of the phase 3 trials, EMERGE, linked aducanumab to improvements on a clinical dementia scale. ... The preponderance of the data indicates aducanumab doesn’t provide a clinical benefit,’ Skorney wrote in
-
Novel endpoints in the digital age
Every clinical trial has an endpoint, a measure used to determine if the drug in question provides therapeutic benefit. ... measure safety, efficacy and clinical benefit of a medicine in a trial.
Alzheimer’s disease: the search for a cure
The search for effective drug treatments for COVID-19
Addressing the payer-regulator evidence gap in early-stage cancer
Alzheimer’s: the search for a cure
Novel endpoints in the digital age
More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.
Latest appointments
-
Dr Irina Antonijevic joins vasopharm
In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203. ... Not only will we benefit from her clinical capabilities in our ongoing pivotal study of
-
ICON's CEO named chair of ACRO
Trade body for clinical research organisation elects Ciaran Murray. The global trade body for clinical research organisations has elected ICON's CEO Ciaran Murray as chairman. ... I look forward to continuing the work that ACRO has done in promoting our
-
Industry veteran Louis Nisbet joins Sygnature board
The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.
Dr Irina Antonijevic joins vasopharm
ICON's CEO named chair of ACRO
Industry veteran Louis Nisbet joins Sygnature board
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
The future of dementia and the important role of healthcare communication in raising awareness
Patients would benefit most from a disease-slowing or modifying therapy but symptomatic treatments with improved clinical profiles would also make a difference to their lives. ... This allows for an accelerated approval for treatments based on biomarkers
-
Don’t limit diversity to just representation in clinical trials
So, here are 3 areas of clinical trial recruitment that could benefit from the workplace being more diverse. ... So, ask yourself: who is doing the community outreach for your clinical trial?
-
Is social media for clinical trial recruitment justified?
Increasing patient’s awareness and education about clinical trials is key in successful clinical trial recruitment strategies. ... While there’s clearly some resistance to this approach, collaboration and education about using social media in the
-
#DemandDiversity: Names erased from history: A dive into black history of clinical research
The history of clinical trials. Clinical trials haven’t always been as regulated as they are now. ... that everyone is fairly represented in clinical trials, so that medicine can benefit us all equally.
-
Real-world evidence: breaking boundaries in rare disease
Launch timelines have been delayed and clinical trials have been postponed or suspended. ... As a result, there are several barriers life science companies need to overcome to benefit from RWE in clinical and commercial settings.
The future of dementia and the important role of healthcare communication in raising awareness
Don’t limit diversity to just representation in clinical trials
#DemandDiversity: Names erased from history: A dive into black history of clinical research
More from PMHub
Approximately 0 fully matching, plus 19 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital project manager
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
-
Digital strategist
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- EU approves bluebird bio’s CALD gene therapy Skysona
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Take part in research with Oxford University Press (OUP)
- Medical affairs - the time for change is now
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
